Nektar Therapeutics (NKTR) 18.11 $NKTR
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
PR Newswire - Wed Aug 03, 3:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016.
NKTR: 18.11 (+0.26)
Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85), NKTR: 18.11 (+0.26)
Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26), CERN: 65.01 (+0.47)
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.42 (+1.68), CAH: 79.70 (+0.03), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 306.03 (+0.40), AMGN: 170.13 (+0.07), NKTR: 18.11 (+0.26)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 6.19 (unch), ANIP: 61.42 (+1.68), MRK: 62.90 (+0.11), NKTR: 18.11 (+0.26)
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 51.11 (+0.01), INCY: 80.81 (-0.29), ARIA: 10.19 (-0.15), NKTR: 18.11 (+0.26)
AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 11.07 (-0.02), ANIP: 61.42 (+1.68), AZN: 32.60 (-0.21), NKTR: 18.11 (+0.26)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.02 (-0.19), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
Nektar Therapeutics (NKTR) Worth a Look: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:45AM CDT
Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares rise over 6% on the day.
AKAO: 3.99 (+0.22), NKTR: 18.11 (+0.26)
Can Ecolab (ECL) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 5:10PM CDT
Ecolab Inc. (ECL) is slated to announce second-quarter 2016 earnings results on Aug 2, 2016.
ZTS: 51.11 (+0.01), CYTR: 0.58 (+0.02), NKTR: 18.11 (+0.26), ECL: 123.10 (+0.05)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.07 (-0.02), ANIP: 61.42 (+1.68), ALXN: 125.63 (-0.23), NKTR: 18.11 (+0.26)
Weight Watchers (WTW) Q2 Earnings: A Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:57AM CDT
Weight management service provider Weight Watchers International Inc. is scheduled to release second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), CYTR: 0.58 (+0.02), WTW: 10.26 (-0.25), NKTR: 18.11 (+0.26)
Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets
PR Newswire - Wed Jul 27, 4:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
NKTR: 18.11 (+0.26)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.78 (-0.09), ARLZ: 5.02 (+0.05), INFI: 1.52 (unch), NKTR: 18.11 (+0.26)
Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
PR Newswire - Mon Jun 06, 1:00PM CDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016.
NKTR: 18.11 (+0.26)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
PR Newswire - Thu Jun 02, 5:30PM CDT
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
NKTR: 18.11 (+0.26)
Nektar Therapeutics Announces Executive Management Promotions
PR Newswire - Thu Jun 02, 3:30PM CDT
Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as Senior Vice President, General Counsel and Secretary of Nektar since 2007.
NKTR: 18.11 (+0.26)
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 61.42 (+1.68), PFE: 34.68 (-0.12), BMY: 56.76 (-0.63), NKTR: 18.11 (+0.26)
Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD(TM) (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
PR Newswire - Wed Jun 01, 7:15AM CDT
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world.
NKTR: 18.11 (+0.26)
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
PR Newswire - Wed Aug 03, 3:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016.
NKTR: 18.11 (+0.26)
Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85), NKTR: 18.11 (+0.26)
Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26), CERN: 65.01 (+0.47)
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.42 (+1.68), CAH: 79.70 (+0.03), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 306.03 (+0.40), AMGN: 170.13 (+0.07), NKTR: 18.11 (+0.26)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 6.19 (unch), ANIP: 61.42 (+1.68), MRK: 62.90 (+0.11), NKTR: 18.11 (+0.26)
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 51.11 (+0.01), INCY: 80.81 (-0.29), ARIA: 10.19 (-0.15), NKTR: 18.11 (+0.26)
AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 11.07 (-0.02), ANIP: 61.42 (+1.68), AZN: 32.60 (-0.21), NKTR: 18.11 (+0.26)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.02 (-0.19), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)
Nektar Therapeutics (NKTR) Worth a Look: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:45AM CDT
Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares rise over 6% on the day.
AKAO: 3.99 (+0.22), NKTR: 18.11 (+0.26)
Can Ecolab (ECL) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 5:10PM CDT
Ecolab Inc. (ECL) is slated to announce second-quarter 2016 earnings results on Aug 2, 2016.
ZTS: 51.11 (+0.01), CYTR: 0.58 (+0.02), NKTR: 18.11 (+0.26), ECL: 123.10 (+0.05)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 11.07 (-0.02), ANIP: 61.42 (+1.68), ALXN: 125.63 (-0.23), NKTR: 18.11 (+0.26)
Weight Watchers (WTW) Q2 Earnings: A Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:57AM CDT
Weight management service provider Weight Watchers International Inc. is scheduled to release second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), CYTR: 0.58 (+0.02), WTW: 10.26 (-0.25), NKTR: 18.11 (+0.26)
Nektar to Announce Financial Results for the Second Quarter 2016 on Wednesday, August 3, 2016, After Close of U.S.-Based Financial Markets
PR Newswire - Wed Jul 27, 4:15PM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2016, on Wednesday, August 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
NKTR: 18.11 (+0.26)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.78 (-0.09), ARLZ: 5.02 (+0.05), INFI: 1.52 (unch), NKTR: 18.11 (+0.26)
Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
PR Newswire - Mon Jun 06, 1:00PM CDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016.
NKTR: 18.11 (+0.26)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
PR Newswire - Thu Jun 02, 5:30PM CDT
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
NKTR: 18.11 (+0.26)
Nektar Therapeutics Announces Executive Management Promotions
PR Newswire - Thu Jun 02, 3:30PM CDT
Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as Senior Vice President, General Counsel and Secretary of Nektar since 2007.
NKTR: 18.11 (+0.26)
Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 61.42 (+1.68), PFE: 34.68 (-0.12), BMY: 56.76 (-0.63), NKTR: 18.11 (+0.26)
Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD(TM) (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
PR Newswire - Wed Jun 01, 7:15AM CDT
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world.
NKTR: 18.11 (+0.26)
